Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00054211" target="_blank" >RIV/00216224:14110/11:00054211 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/11:#0001204

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II

Popis výsledku v původním jazyce

Purpose: To report results of retrospective, consecutive, noncomparative case series of moderate and severe stage 3 retinopathy of prematurity (ROP) in zone I or posterior zone II treated by bilateral intravitreal injections of pegaptanib or bevacizumaband diode laser photocoagulation. 32 infants weighing from 545 g to 1,150 g at birth (mean, 742.8 g) with gestational ages from 22 weeks to 28 weeks (mean, 24.1 weeks) received intravitreal injections of pegaptanib (0,15mg) or bevacizumab (0.625 mg ) at9.0 weeks to 14.0 weeks of age (mean, 10.5 weeks) and after 1 week had diode laser therapy. Length of follow-up was from 15.0 weeks to 95.0 weeks (mean, 56.5 weeks). Only patients with bilateral moderate or severe stage 3 ROP in Zone I or posterior ZoneII with or without plus-disease were considered candidates for this study. All cases were photographed by the RetCam Imaging System immediately before and 1week, 1,2, and 3months after the bilateral treatment.

Název v anglickém jazyce

Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II

Popis výsledku anglicky

Purpose: To report results of retrospective, consecutive, noncomparative case series of moderate and severe stage 3 retinopathy of prematurity (ROP) in zone I or posterior zone II treated by bilateral intravitreal injections of pegaptanib or bevacizumaband diode laser photocoagulation. 32 infants weighing from 545 g to 1,150 g at birth (mean, 742.8 g) with gestational ages from 22 weeks to 28 weeks (mean, 24.1 weeks) received intravitreal injections of pegaptanib (0,15mg) or bevacizumab (0.625 mg ) at9.0 weeks to 14.0 weeks of age (mean, 10.5 weeks) and after 1 week had diode laser therapy. Length of follow-up was from 15.0 weeks to 95.0 weeks (mean, 56.5 weeks). Only patients with bilateral moderate or severe stage 3 ROP in Zone I or posterior ZoneII with or without plus-disease were considered candidates for this study. All cases were photographed by the RetCam Imaging System immediately before and 1week, 1,2, and 3months after the bilateral treatment.

Druh

O - Ostatní výsledky

CEP obor

FF - ORL, oftalmologie, stomatologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NS9892" target="_blank" >NS9892: Přínos intravitreální aplikace selektivního inhibitoru vaskulárního endoteliálního růstového faktoru (anti-VEGF), pegaptanibu sodného, v léčbě retinopatie nedonošených.</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů